MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/heartjnl-2016-309832

Медицинская библиотека · Heart (British Cardiac Society) · 2016

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm A John, Accetta Gabriele, Ambrosio Giuseppe, Atar Dan, Bassand Jean-Pierre, Berge Eivind, Cools Frank, Fitzmaurice David A, Goldhaber Samuel Z, Goto Shinya, Haas Sylvia, Kayani Gloria, Koretsune Yukihiro, Mantovani Lorenzo G, Misselwitz Frank, Oh Seil, Turpie Alexander G G, Verheugt Freek W A, Kakkar Ajay K, GARFIELD-AF Investigators

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

We studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 and 2015.

METHODS

39 670 patients were prospectively enrolled in four sequential cohorts in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): cohort C1 (2010-2011), n=5500; C2 (2011-2013), n=11 662; C3 (2013-2014), n=11 462; C4 (2014-2015), n=11 046. Baseline characteristics and antithrombotic therapy initiated at diagnosis were analysed by cohort.

RESULTS

Baseline characteristics were similar across cohorts. Median CHA2DS2-VASc (cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)) score was 3 in all four cohorts. From C1 to C4, the proportion of patients on anticoagulant (AC) therapy increased by almost 15% (C1 57.4%; C4 71.1%). Use of vitamin K antagonist (VKA)±antiplatelet (AP) (C1 53.2%; C4 34.0%) and AP monotherapy (C1 30.2%; C4 16.6%) declined, while use of non-VKA oral ACs (NOACs)±AP increased (C1 4.2%; C4 37.0%). Most CHA2DS2-VASc ≥2 patients received AC, and this proportion increased over time, largely driven by NOAC prescribing. NOACs were more frequently prescribed than VKAs in men, the elderly, patients of Asian ethnicity, those with dementia, or those using non-steroidal anti-inflammatory drugs, and current smokers. VKA use was more common in patients with cardiac, vascular, or renal comorbidities.

CONCLUSIONS

Since NOACs were introduced, there has been an increase in newly diagnosed patients with AF at risk of stroke receiving guideline-recommended therapy, predominantly driven by increased use of NOACs and reduced use of VKA±AP or AP alone.

TRIAL REGISTRATION NUMBER: NCT01090362; Pre-results.

Для цитирования: Camm A John, Accetta Gabriele, Ambrosio Giuseppe, Atar Dan, Bassand Jean-Pierre, Berge Eivind, Cools Frank, Fitzmaurice David A, Goldhaber Samuel Z, Goto Shinya, Haas Sylvia, Kayani Gloria, Koretsune Yukihiro, Mantovani Lorenzo G, Misselwitz Frank, Oh Seil, Turpie Alexander G G, Verheugt Freek W A, Kakkar Ajay K, GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.. Heart (British Cardiac Society). 2016. DOI: 10.1136/heartjnl-2016-309832.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.